Platelet activating factor (PAF) and lyso-PAF in psoriasis.
Previous studies have shown that scale from lesional psoriatic skin contains substantial amounts of platelet activating factor (PAF). In this study, PAF and its immediate precursor, lyso-PAF, were measured in exudates from abrasions on lesional and uninvolved psoriatic skin, and from skin of healthy subjects. The mean amounts of PAF recovered from lesional and uninvolved psoriatic skin (n = 13) and from healthy skin (n = 14) were not significantly different (range 0.05-2.14 pmol/sample). Mean recoveries of lyso-PAF from lesional psoriatic skin (n = 9) and skin of healthy subjects (n = 13) were also similar (9.5 +/- 1.9 and 11.0 +/- 1.9 pmol/sample, respectively), but significantly less lyso-PAF was found in exudates from the uninvolved psoriatic skin (n = 9; 3.1 +/- 0.4 pmol/sample; P < 0.01 relative to both lesional psoriasis and healthy skin). The finding of reduced lyso-PAF in uninvolved psoriatic skin was unexpected because increased phospholipase-A2 activity is associated with psoriasis. These results do not support the hypothesis that extracellular PAF contributes significantly to the inflammation associated with psoriasis.
Judge
M R
MR
St John's Institute of Dermatology, UMDS, St Thomas's Hospital, London, UK.
Barr
R M
RM
Mallet
A I
AI
Courtney
F
F
Kobza Black
A
A
Greaves
M W
MW
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010741:Phospholipases A / Q000502:physiology; D054467:Phospholipases A2; D010972:Platelet Activating Factor / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism*; D011565:Psoriasis / Q000378:metabolism*; D012867:Skin / Q000737:chemistry / Q000378:metabolism / Q000473:pathology
C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor; D010741:Phospholipases A; D054467:Phospholipases A2